Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa A Hammond

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Clinical Lung Cancer|December 4, 2003
Pharmacokinetic evaluation of gefitinib when administered with chemotherapyLisa A Hammond
Dermatologic Clinics|November 21, 2007
Cutaneous reactions related to systemic immunomodulators and targeted therapeuticsLisa A Hammond-Thelin
Oncology|November 8, 2002
HER-targeted tyrosine-kinase inhibitorsJosé Baselga, Lisa A Hammond
Reviews on Recent Clinical Trials|May 14, 2008
Systemic therapeutic options in thymic malignancies: a glimmer of hopeLisa A Hammond-Thelin, Charles R Thomas
Nature Biotechnology|June 4, 2004
An image worth a thousand lives?Lisa A Hammond, Sean X Cavanaugh, Charles R Thomas
Investigational New Drugs|October 28, 2003
Positron emission tomography (PET): expanding the horizons of oncology drug developmentLisa A Hammond, Louis Denis, Umber Salman, et al.
Documenta Ophthalmologica. Advances in Ophthalmology|December 3, 2004
Acute retinal toxicity from the novel anti-tumor agent, IrofulvenRobert F Melendez, Joseph M Harrison, Eric K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumorsScot Ebbinghaus, Eric Rubin, Evan Hersh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancerRomán Pérez-Soler, Abraham Chachoua, Lisa A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignanciesEric K Rowinsky, Muralidhar Beeram, Lisa A Hammond, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Clinical Lung Cancer|December 4, 2003
Pharmacokinetic evaluation of gefitinib when administered with chemotherapyLisa A Hammond
Dermatologic Clinics|November 21, 2007
Cutaneous reactions related to systemic immunomodulators and targeted therapeuticsLisa A Hammond-Thelin
Oncology|November 8, 2002
HER-targeted tyrosine-kinase inhibitorsJosé Baselga, Lisa A Hammond
Reviews on Recent Clinical Trials|May 14, 2008
Systemic therapeutic options in thymic malignancies: a glimmer of hopeLisa A Hammond-Thelin, Charles R Thomas
Nature Biotechnology|June 4, 2004
An image worth a thousand lives?Lisa A Hammond, Sean X Cavanaugh, Charles R Thomas
Investigational New Drugs|October 28, 2003
Positron emission tomography (PET): expanding the horizons of oncology drug developmentLisa A Hammond, Louis Denis, Umber Salman, et al.
Documenta Ophthalmologica. Advances in Ophthalmology|December 3, 2004
Acute retinal toxicity from the novel anti-tumor agent, IrofulvenRobert F Melendez, Joseph M Harrison, Eric K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumorsScot Ebbinghaus, Eric Rubin, Evan Hersh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancerRomán Pérez-Soler, Abraham Chachoua, Lisa A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignanciesEric K Rowinsky, Muralidhar Beeram, Lisa A Hammond, et al.
Pageof 4